MCID: SZR006
MIFTS: 58

Seizure Disorder

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Seizure Disorder

MalaCards integrated aliases for Seizure Disorder:

Name: Seizure Disorder 54 6 3
Seizures 29 6 43
Epilepsy 73
Seizure 29

Classifications:



External Ids:

UMLS 73 C0014544

Summaries for Seizure Disorder

NINDS : 54 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Seizure Disorder, also known as seizures, is related to seizures, benign familial infantile, 3 and malignant migrating partial seizures of infancy, and has symptoms including seizures, tremor and back pain. An important gene associated with Seizure Disorder is MTR (5-Methyltetrahydrofolate-Homocysteine Methyltransferase), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Clobazam and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes, and related phenotype is nervous system.

MedlinePlus : 43 Seizures are symptoms of a brain problem. They happen because of sudden, abnormal electrical activity in the brain. When people think of seizures, they often think of convulsions in which a person's body shakes rapidly and uncontrollably. Not all seizures cause convulsions. There are many types of seizures and some have mild symptoms. Seizures fall into two main groups. Focal seizures, also called partial seizures, happen in just one part of the brain. Generalized seizures are a result of abnormal activity on both sides of the brain. Most seizures last from 30 seconds to 2 minutes and do not cause lasting harm. However, it is a medical emergency if seizures last longer than 5 minutes or if a person has many seizures and does not wake up between them. Seizures can have many causes, including medicines, high fevers, head injuries and certain diseases. People who have recurring seizures due to a brain disorder have epilepsy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 What’s New

Wikipedia : 76 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Seizure Disorder

Diseases in the Seizure Disorder family:

Seizures, Benign Familial Infantile, 1 Seizures, Benign Familial Infantile, 2
Seizures, Benign Familial Infantile, 3 Seizures, Benign Familial Infantile, 4
Seizures, Benign Familial Infantile, 5 Scn1a-Related Seizure Disorders

Diseases related to Seizure Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1852)
# Related Disease Score Top Affiliating Genes
1 seizures, benign familial infantile, 3 33.8 KCNQ2 SCN1A SCN2A
2 malignant migrating partial seizures of infancy 33.7 SCN1A SCN2A TBC1D24
3 benign neonatal seizures 33.7 KCNQ2 SCN2A
4 generalized epilepsy with febrile seizures plus 33.5 KCNQ2 SCN1A SCN2A TBC1D24
5 epilepsy with generalized tonic-clonic seizures 33.4 SCN1A SCN2A TBC1D24
6 epilepsy, idiopathic generalized 10 33.0 ICK SCN1A SCN2A TBC1D24
7 benign familial neonatal epilepsy 32.9 KCNQ2 SCN2A TBC1D24
8 benign familial infantile epilepsy 32.8 KCNQ2 PNPO SCN2A
9 benign epilepsy with centrotemporal spikes 32.5 CELF4 KCNQ2 SCN2A TBC1D24
10 epilepsy, nocturnal frontal lobe, 1 32.0 KCNQ2 SCN1A
11 early infantile epileptic encephalopathy 31.9 CDKL5 KCNQ2 SCN1A SCN2A TBC1D24
12 epilepsy, idiopathic generalized 31.7 CDKL5 KCNQ2 SCN1A SCN2A TBC1D24
13 infantile epileptic encephalopathy 31.7 CDKL5 SCN1A SCN2A
14 west syndrome 31.5 CDKL5 KCNQ2 MECP2 SCN1A SCN2A TBC1D24
15 early myoclonic encephalopathy 31.5 CDKL5 SCN1A TBC1D24
16 focal epilepsy 31.5 CDKL5 SCN1A SCN2A TBC1D24
17 epilepsy, familial temporal lobe, 3 31.3 NLGN1 SCN2A
18 epileptic encephalopathy, early infantile, 9 31.1 CDKL5 MECP2 SCN1A
19 visual epilepsy 31.1 CDKL5 KCNQ2 MECP2 PNPO SCN1A SCN2A
20 epileptic encephalopathy, early infantile, 1 31.0 KCNQ2 TBC1D24
21 epileptic encephalopathy, early infantile, 6 30.6 CDKL5 KCNQ2 PNPO SCN1A SCN2A TBC1D24
22 alacrima, achalasia, and mental retardation syndrome 29.6 MECP2 SCN1A TBC1D24
23 epilepsy 29.5 CDKL5 ICK KCNQ2 MECP2 PNPO SCN1A
24 encephalopathy 29.4 CDKL5 MECP2 PNPO SCN1A
25 pervasive developmental disorder 29.0 CDKL5 MECP2 NLGN1
26 autism 28.8 CDKL5 MECP2 NLGN1 SCN1A SCN2A SEZ6L2
27 scn1a-related seizure disorders 12.3
28 dissociative seizures 12.3
29 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 12.3
30 multiple congenital anomalies-hypotonia-seizures syndrome 2 12.3
31 multiple congenital anomalies-hypotonia-seizures syndrome 3 12.3
32 multiple congenital anomalies-hypotonia-seizures syndrome 1 12.3
33 febrile seizures, familial, 4 12.3
34 microcephaly, seizures, and developmental delay 12.2
35 kifafa seizure disorder 12.2
36 epilepsy with myoclonic-atonic seizures 12.2
37 dandy-walker malformation with intellectual disability, basal ganglia disease and seizures 12.2
38 microcephaly, short stature, and polymicrogyria with or without seizures 12.2
39 seizures, benign familial infantile, 2 12.2
40 generalized epilepsy with febrile seizures plus, type 9 12.2
41 seizures, benign familial neonatal, 2 12.2
42 seizures, benign familial neonatal, 1 12.2
43 rigidity and multifocal seizure syndrome, lethal neonatal 12.2
44 microcephaly, progressive, with seizures and cerebral and cerebellar atrophy 12.2
45 cerebellar atrophy, developmental delay, and seizures 12.1
46 microcephaly, postnatal progressive, with seizures and brain atrophy 12.1
47 seizures, cortical blindness, and microcephaly syndrome 12.1
48 primary aldosteronism, seizures, and neurologic abnormalities 12.1
49 seizures, scoliosis, and macrocephaly syndrome 12.1
50 seizures, benign familial infantile, 5 12.1

Comorbidity relations with Seizure Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Seizure Disorder:



Diseases related to Seizure Disorder

Symptoms & Phenotypes for Seizure Disorder

UMLS symptoms related to Seizure Disorder:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, non-epileptic convulsion

MGI Mouse Phenotypes related to Seizure Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 CDKL5 CELF4 DIAPH1 ICK KCNQ2 MECP2

Drugs & Therapeutics for Seizure Disorder

Drugs for Seizure Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 605)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 22316-47-8 2789
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
6
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
7
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
8
Tiagabine Approved, Investigational Phase 4,Phase 1 115103-54-3 60648
9
Felbamate Approved Phase 4 25451-15-4 3331
10
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 1622-61-3 2802
11
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
12
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
13
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-06-6 4763
14
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
15
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28721-07-5 34312
16
Vigabatrin Approved Phase 4,Phase 3,Phase 2,Not Applicable 60643-86-9, 68506-86-5 5665
17
Zonisamide Approved, Investigational Phase 4,Phase 3,Not Applicable 68291-97-4 5734
18
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
19
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
20
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-41-0 1775
21
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
22
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
23
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
24 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7491-74-9
25
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
27
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
28
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
29
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 439-14-5 3016
30
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
31
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
32
Biperiden Approved, Investigational Phase 4,Phase 3 514-65-8 2381
33
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
34
Atropine Approved, Vet_approved Phase 4,Not Applicable 51-55-8, 5908-99-6 174174
35
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
36
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175481-36-4, 860352-01-8 219078
37
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75970-99-9, 236395-14-5 123618
38
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
39 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
41
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
44
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
45
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
46
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
47
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
48
Levonorgestrel Approved, Investigational Phase 4,Phase 1 17489-40-6, 797-63-7 13109
49
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
50
Tocopherol Approved, Investigational Phase 4,Early Phase 1 1406-66-2 14986

Interventional clinical trials:

(show top 50) (show all 1824)
# Name Status NCT ID Phase Drugs
1 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
2 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
5 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
6 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
7 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
8 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients Unknown status NCT02404168 Phase 4 lamotrigine (brand Lamictal);lamotrigine (generic Teva)
9 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
10 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
11 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
12 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
13 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
14 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
15 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
16 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
17 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
18 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
19 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
20 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
21 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
22 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4 Phenytoin;placebo
23 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
24 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
25 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
26 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
27 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
28 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
29 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4 Methylphenidate
30 Characterization of Epilepsy Patients BEEP 2b Completed NCT02707965 Phase 4 Oxcarbmazepine (brand name vs generic drugs);Divalproex Sodium (brand name vs generic drugs);Carbamazepine (brand name vs generic drugs);Lamotrigine (brand name vs generic drugs);levetiracetam (brand name vs generic drugs);Topiramate (brand name vs generic drugs);Zonisamide (brand name vs generic drugs);Phenytoin sodium (brand name vs generic drugs)
31 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
32 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
33 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4 Levetiracetam
34 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4 topamax
35 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
36 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4 levetiracetam
37 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
38 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
39 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4 lamotrigine
40 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4 Topiramate
41 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Completed NCT00955357 Phase 4 Lacosamide
42 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4 Cholecalciferol
43 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4 valproate microgranules
44 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4 Levetiracetam (Keppra)
45 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4 Levetiracetam;Oxcarbazepine
46 Lamotrigine Bioequivalence Completed NCT01995825 Phase 4 lamotrigine
47 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
48 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4 Levetiracetam
49 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Completed NCT00266604 Phase 4 Topiramate
50 Switchability Study Between Brand and Generic Topiramate Completed NCT02113787 Phase 4

Search NIH Clinical Center for Seizure Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Seizure Disorder

Genetic tests related to Seizure Disorder:

# Genetic test Affiliating Genes
1 Seizures 29
2 Seizure 29

Anatomical Context for Seizure Disorder

MalaCards organs/tissues related to Seizure Disorder:

41
Brain, Bone, Testes, Temporal Lobe, Liver, Heart, Cortex

Publications for Seizure Disorder

Articles related to Seizure Disorder:

(show top 50) (show all 1123)
# Title Authors Year
1
Subjective and physiological response to emotions in temporal lobe epilepsy and psychogenic non-epileptic seizures. ( 30312840 )
2019
2
Positive modulation of mGluR5 attenuates seizures and reduces TNF-α+ macrophages and microglia in the brain in a murine model of virus-induced temporal lobe epilepsy. ( 30316834 )
2019
3
Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. ( 30478005 )
2019
4
Generalized seizures evoked by nucleus accumbens stimulation induced an opiate-mediated suppression of psychosis relevant behaviors. ( 30218680 )
2019
5
Serum Procalcitonin Levels in Acute Encephalopathy with Biphasic Seizures and Late Reduced Diffusion. ( 29725488 )
2018
6
Vascular pathomechanism in acute encephalopathy with biphasic seizures and late reduced diffusion. ( 30317181 )
2018
7
Acute encephalopathy with biphasic seizures and late reduced diffusion accompanied by Takotsubo cardiomyopathy. ( 30327157 )
2018
8
Alcohol-related seizures may be associated with more severe depression, alcohol dependence syndrome, and more pronounced alcohol-related problems. ( 30470458 )
2018
9
Post-traumatic stress and relationships to coping and alexithymia in patients with psychogenic non-epileptic seizures. ( 29573595 )
2018
10
Gender differences in prevalence of psychiatric disorders, levels of alexithymia, and coping strategies in patients with refractory mesial temporal epilepsy and comorbid psychogenic nonepileptic seizures. ( 29574297 )
2018
11
Syncopal Episodes of Arrhythmogenic Right Ventricular Cardiomyopathy in a Patient with Pre-existing Seizure Disorder. ( 30094117 )
2018
12
Giant intracranial arteriovenous malformation as the focus of epileptic seizures. ( 29139152 )
2018
13
Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer. ( 30297193 )
2018
14
Clinical Trial of Efficacy Evaluation of Omega-3 with Risperidone on Seizures Frequency in Children with Refractory Epilepsy and Attention-Deficit/Hyperactivity Disorder. ( 30279706 )
2018
15
Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy. ( 30089215 )
2018
16
Attention-deficit/hyperactivity disorder medication and seizures. ( 29476037 )
2018
17
Transcriptome of the Wistar audiogenic rat (WAR) strain following audiogenic seizures. ( 30193173 )
2018
18
Deletion of Long Isoform of Eukaryotic Elongation Factor 1Bδ Leads to Audiogenic Seizures and Aversive Stimulus-Induced Long-Lasting Activity Suppression in Mice. ( 30333725 )
2018
19
A 17-Year-Old Boy With High-Functioning Autism, Gastrointestinal Illness, and Seizures. ( 30545828 )
2018
20
Focal Electrographic Seizures in a Patient With Autism Spectrum Disorder and Speech Delay. ( 30461592 )
2018
21
A recurrent de novo CUX2 missense variant associated with intellectual disability, seizures, and autism spectrum disorder. ( 29795476 )
2018
22
Electroclinical features of seizures associated with autoimmune encephalitis. ( 30031297 )
2018
23
Hippocampal Functional Dynamics Are Clinically Implicated in Autoimmune Encephalitis With Faciobrachial Dystonic Seizures. ( 30233485 )
2018
24
Clinical Features at the Time of Diagnosis of Benign Epilepsy With Centrotemporal Spikes Do Not Predict Subsequent Seizures. ( 30337131 )
2018
25
Neuroinflammation and Seizures After Pediatric Brain Injury: What a Headache! ( 30254521 )
2018
26
Nationwide incidence and risk factors for posttraumatic seizures in children with traumatic brain injury. ( 30239282 )
2018
27
Psychiatric comorbidity and traumatic brain injury attribution in patients with psychogenic nonepileptic or epileptic seizures: A multicenter study of US veterans. ( 30144027 )
2018
28
Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents. ( 30115757 )
2018
29
The Effect of Keppra Prophylaxis on the Incidence of Early Onset, Post-traumatic Brain Injury Seizures. ( 30050729 )
2018
30
Contributions of the Hippocampal CA3 Circuitry to Acute Seizures and Hyperexcitability Responses in Mouse Models of Brain Ischemia. ( 30210302 )
2018
31
Long-term risk of seizures among cardiac arrest survivors. ( 29932947 )
2018
32
Seize the day and seize seizures after cardiac arrest. ( 29246743 )
2018
33
Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy. ( 29691655 )
2018
34
Long-term Seizure Disorder Caused by a Dermoid Cyst with Catastrophic Developments. ( 30443443 )
2018
35
Recurrent Seizures in 2 Patients with Magnesium Sulfate-Treated Eclampsia at a Secondary Hospital. ( 30250014 )
2018
36
Clinical and imaging profile of patients with new-onset seizures & a presumptive diagnosis of eclampsia - A prospective observational study. ( 29674196 )
2018
37
Refractory Hypoglycemia and Seizures as the Initial Presenting Manifestation of Empty Sella Syndrome. ( 30116682 )
2018
38
Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. ( 30460450 )
2018
39
Faciobrachial dystonic seizures expressed as epileptic spasms, followed by focal seizures in anti-LGI1 encephalitis: a video-polygraphic study. ( 30530418 )
2018
40
Electrographic Seizures in Patients with Acute Encephalitis. ( 30203384 )
2018
41
Clinical and electrographic characteristics of seizures in LGI1-antibody encephalitis. ( 30332659 )
2018
42
Acute encephalopathy with biphasic seizures and late diffusion restriction in scrub typhus encephalitis. ( 30039462 )
2018
43
Chemokine receptors CCR2 and CX3CR1 regulate viral encephalitis-induced hippocampal damage but not seizures. ( 30181265 )
2018
44
Severe GABAA receptor encephalitis without seizures: A paediatric case successfully treated with early immunomodulation. ( 29396172 )
2018
45
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. ( 29131884 )
2018
46
KCNQ2 mutation in an infant with encephalopathy of infancy with migrating focal seizures. ( 30530441 )
2018
47
A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic-ischemic encephalopathy. ( 30296665 )
2018
48
Seizures in newborn infants without hypoxic ischemic encephalopathy - antenatal and labor-related risk factors: a case-control study. ( 30373414 )
2018
49
Short "Infraslow" Activity (SISA) With Burst Suppression in Acute Anoxic Encephalopathy: A Rare, Specific Ominous Sign With Acute Posthypoxic Myoclonus or Acute Symptomatic Seizures. ( 30387784 )
2018
50
Development of permanent brain damage after subacute encephalopathy with seizures in alcoholics. ( 30391820 )
2018

Variations for Seizure Disorder

ClinVar genetic disease variations for Seizure Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MTR NM_000254.2(MTR): c.3518C> T (p.Pro1173Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913578 GRCh37 Chromosome 1, 237058770: 237058770
2 MTR NM_000254.2(MTR): c.3518C> T (p.Pro1173Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913578 GRCh38 Chromosome 1, 236895470: 236895470
3 SCN1A NM_006920.4(SCN1A): c.1625G> A (p.Arg542Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs121918817 GRCh37 Chromosome 2, 166901590: 166901590
4 SCN1A NM_006920.4(SCN1A): c.1625G> A (p.Arg542Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs121918817 GRCh38 Chromosome 2, 166045080: 166045080
5 DIAPH1 NM_001079812.2(DIAPH1): c.2305C> T (p.Gln769Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730882242 GRCh38 Chromosome 5, 141573518: 141573518
6 DIAPH1 NM_001079812.2(DIAPH1): c.2305C> T (p.Gln769Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730882242 GRCh37 Chromosome 5, 140953085: 140953085

Expression for Seizure Disorder

Search GEO for disease gene expression data for Seizure Disorder.

Pathways for Seizure Disorder

Pathways related to Seizure Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 KCNQ2 MECP2 SCN1A SCN2A
2
Show member pathways
11.43 KCNQ2 SCN1A SCN2A
3 10.28 KCNQ2 SCN1A SCN2A

GO Terms for Seizure Disorder

Cellular components related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon initial segment GO:0043194 9.26 KCNQ2 SCN1A
2 voltage-gated sodium channel complex GO:0001518 9.16 SCN1A SCN2A
3 sodium channel complex GO:0034706 8.96 SCN1A SCN2A
4 node of Ranvier GO:0033268 8.8 KCNQ2 SCN1A SCN2A

Biological processes related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of ion transmembrane transport GO:0034765 9.54 KCNQ2 SCN1A SCN2A
2 neuron projection development GO:0031175 9.5 MECP2 NLGN1 TBC1D24
3 neuronal action potential GO:0019228 9.4 SCN1A SCN2A
4 positive regulation of dendritic spine development GO:0060999 9.26 CDKL5 NLGN1
5 membrane depolarization during action potential GO:0086010 9.16 SCN1A SCN2A
6 neuromuscular process controlling posture GO:0050884 8.96 MECP2 SCN1A
7 regulation of respiratory gaseous exchange by neurological system process GO:0002087 8.62 MECP2 NLGN1

Molecular functions related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium channel activity GO:0005272 9.16 SCN1A SCN2A
2 voltage-gated ion channel activity GO:0005244 9.13 KCNQ2 SCN1A SCN2A
3 voltage-gated sodium channel activity GO:0005248 8.62 SCN1A SCN2A

Sources for Seizure Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....